| Title: | Blood pressure, calcium channel blockers, and the risk of prostate cancer: a Mendelian randomization study |
| Journal: | Cancer Causes & Control |
| Published: | 13 May 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37178364/ |
| DOI: | https://doi.org/10.1007/s10552-023-01712-z |
Publication 11445
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundObservational studies have found some evidence of an association between elevated blood pressure and prostate cancer risk; however, the results are inconclusive. We tested whether systolic blood pressure (SBP) influences prostate cancer risk and evaluated the effect of calcium channel blockers (CCB) on the disease using Mendelian randomization (MR) approach.MethodsWe used 278 genetic variants associated with SBP and 16 genetic variants in CCB genes as instrumental variables. Effect estimates were obtained from the UK Biobank sample of 142,995 males and from PRACTICAL consortium (79,148 cases and 61,106 controls).ResultsFor each 10 mm Hg increase in SBP the estimated effect was OR 0.96 (0.90-1.01) for overall prostate cancer; and OR 0.92 (0.85-0.99) for aggressive prostate cancer. The MR-estimated effect of a 10 mm Hg- SBP lowering through CCB genetic variants was OR 1.22 (1.06-1.42) for all prostate cancers and OR 1.49 (1.18-1.89) for aggressive prostate cancer.ConclusionThe results of our study did not support a causal relationship between SBP and prostate cancer; however, we found weak evidence of a protective effect of high SBP on aggressive prostate cancer and we found that blocking calcium channel receptors may increase prostate cancer risk.</p>
5 Authors
- Nabila Kazmi
- Elena V. Valeeva
- Gulshat R. Khasanova
- Sarah J. Lewis
- Denis Plotnikov
Enabling scientific discoveries that improve human health